ClinicalTrials.gg

Program

Pan-KRAS Inhibitor AUBE00

In Hoffmann-La Roche’s pipeline, pan-KRAS inhibitor. Its studies are led by Hoffmann-La Roche.

Furthest: phase 1, since May 11, 20251 company-led study, 1 open or runningNext primary completion: Dec 31, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche11 open or runningphase 1since May 11, 2025May 11, 2025Dec 31, 2029phase 1 · NCT07030959
  • Named in Hoffmann-La Roche’s own pipeline as CHU AUBE00 pan-KRAS inhibitor, phase 1, as of Oct 22, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 11, 2025First study: phase 1 study in Solid TumorsFirst studyNCT07030959 · 130 planned · United States, Japan

Ahead

  1. Dec 31, 2029Primary completion: phase 1 study in Solid TumorsNCT07030959

TargetBeta

“pan-KRAS inhibitor”the company's pipeline, read by Claude · source
“An orally bioavailable cyclic peptide and inhibitor of various oncogenic KRAS mutations, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07030959Solid Tumors · United States, Japan1RecruitingDec 31, 2029130

How it is read

Names in the registry

  • “AUBE00”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.